CSF1R and colorectal cancer: Interestingly, in colorectal cancer, peritoneal‐resident immunosuppressive macrophages exhibit high expression levels of CSF1R, including SPP1+ macrophage populations.[31] Moreover, anti‐CSF1R antibody treatment has been shown to deplete all pro‐inflammatory anti‐tumor macrophages.[31] This observation raises the critical question of whether CSF1R‐targeting antibody therapy for fibrotic diseases could concurrently deplete pro‐fibrotic SPP1+ macrophages.